6620-60-6 Usage
Description
Proglumide, also known as Milid and Nulsa, is a nonpeptide, orally active cholecystokinin (CCK)-A/B receptor antagonist. It is a white solid that selectively blocks the effects of cholecystokinin in the central nervous system (CNS). Proglumide has the ability to inhibit gastric secretion and protect the gastroduodenal mucosa. Additionally, it exhibits antiepileptic and antioxidant activities.
Uses
Used in Pharmaceutical Industry:
Proglumide is used as an anticholinergic agent for inhibiting gastrointestinal motility and reducing gastric secretions. It acts as a cholecystokinin antagonist, blocking both the CCKA and CCKB subtypes, and was primarily used in the treatment of stomach ulcers. However, it has now been largely replaced by newer drugs for this application.
Used in Neurological Applications:
Proglumide is used as a CNS modulator for selectively blocking the effects of cholecystokinin in the central nervous system. This property makes it a potential candidate for the treatment of neurological disorders.
Used in Gastrointestinal Protection:
Proglumide is used as a gastroprotective agent for inhibiting gastric secretion and protecting the gastroduodenal mucosa, which can help in the management of gastrointestinal disorders.
Used in Antioxidant and Antiepileptic Applications:
Proglumide is used as an antioxidant and antiepileptic agent due to its ability to exhibit these activities, making it a potential candidate for the treatment of oxidative stress-related and seizure disorders.
Side effects
An interesting side effect of proglumide is that it enhances the analgesia produced by opioid drugs, and can prevent or even reverse the development of tolerance to opioid drugs. This can make it a useful adjuvant treatment to use alongside opioid drugs in the treatment of chronic pain conditions such as cancer, where opioid analgesics may be required for long periods and development of tolerance reduces clinical efficacy of these drugs.Proglumide has also been shown to act as a δ-opioid agonist, which may contribute to its analgesic effects.
Safety Profile
Moderately toxic by severalroutes. An experimental teratogen. When heated todecomposition it emits toxic fumes of NOx.
Enzyme inhibitor
This anticholinergic agent (FWfree-acid = 334.42 g/mol; CAS 6620-60-6), also known as DL-4-benzamido-N,N-dipropylglutaramic acid and 4- (benzoylamino)-5-(dipropylamino)-5-oxopentanoic acid, is a cholecystokinin receptor antagonist. Proglumide A also exerts an inhibitory effect on gastric secretion and reduces gastrointestinal motility. It finds use clinically as a therapy for gastrointestinal ulcers. Target(s): cholecystokinin receptor; gastrin receptor.
Check Digit Verification of cas no
The CAS Registry Mumber 6620-60-6 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 6,6,2 and 0 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 6620-60:
(6*6)+(5*6)+(4*2)+(3*0)+(2*6)+(1*0)=86
86 % 10 = 6
So 6620-60-6 is a valid CAS Registry Number.
InChI:InChI=1/C18H26N2O4/c1-3-12-20(13-4-2)18(24)15(10-11-16(21)22)19-17(23)14-8-6-5-7-9-14/h5-9,15H,3-4,10-13H2,1-2H3,(H,19,23)(H,21,22)
6620-60-6Relevant articles and documents
Generation of Oxyphosphonium Ions by Photoredox/Cobaloxime Catalysis for Scalable Amide and Peptide Synthesis in Batch and Continuous-Flow
Chen, Xiangyang,Houk, Kendall N.,Mo, Jia-Nan,Su, Junqi,Umanzor, Alexander,Zhang, Zheng,Zhao, Jiannan
, (2022/01/06)
Phosphine-mediated deoxygenative nucleophilic substitutions, such as the Mitsunobu reaction, are of great importance in organic synthesis. However, the conventional protocols require stoichiometric oxidants to trigger the formation of the oxyphosphonium i
New glutamic and aspartic derivatives with potent CCK-antagonistic activity
Makovec,Chiste,Bani,et al.
, p. 9 - 20 (2007/10/02)
New derivatives of aspartic and glutamic acid were synthesized and evaluated in vitro and in vivo for anti-CCK activity on the guinea pig gallbladder. The anti-CCK activity of some 4-benzamido-glutaramic acid derivatives was a hundred times greater than that of proglutamide, the model compound, and they have been selected for further studies.